Peru Instructions for Use: Instrucciones de Uso Content Requirements for Registration
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
Regulatory information verified as of October 29, 2026
1. Key takeaways
The instructions for use, the Instrucciones de Uso or IFU, are a mandatory component of the registration dossier in Peru: item 7 of Class I and item 6 of the IVD pathway both explicitly require a Spanish-language version. The content list is set by the instructions for use chapter of D.S. N° 016-2011-SA, published on 2011-07-27, with additional provisions for special situations such as sterility indication, validity claims, irradiation, accuracy, and implants, specific article numbers pending verification, subject to the official publication. An IFU is not an expanded label. It answers a different question: how a user safely completes a task on the basis of this document alone. Files that treat the IFU as marketing copy with operating steps appended fail because the identification, claims, and risk sections that frame those steps are missing or buried.
2. Legal basis
| Regulation | Number | Publication date | Provision or key point |
|---|---|---|---|
| Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos, Dispositivos Médicos y Productos Sanitarios | D.S. N° 016-2011-SA | 2011-07-27 | Instructions for use chapter: content list and additions for special devices, specific article numbers pending verification, subject to the official publication; Article 124 item 7 requires submission of the Spanish IFU |
| Modificatoria del D.S. N° 016-2011-SA | D.S. N° 016-2017-SA | 2017-06-07 | Amends the Title IV technical documentation provisions and the wording system |
| Reglamento para el Registro, Control y Vigilancia Sanitaria de Productos Farmacéuticos y Afines | D.S. N° 010-97-SA | 1997-12-23 | Item 6, the Spanish IFU, under the IVD pathway |
| Modificatoria del D.S. N° 016-2011-SA | D.S. N° 001-2012-SA | 2012-01-22 | First supplementary transitional provision directs IVDs to D.S. N° 010-97-SA |
| Reglamento que establece las Reglas de Clasificación y los Principios Esenciales de Seguridad y Desempeño | D.S. N° 003-2020-SA | 2020-02-06 | The Essential Principles framework defines the risk statements and validity-related explanations the IFU must cover |
Regulatory information verified as of October 29, 2026.
3. Expert insights
Insight 1: The content list follows a cognitive path of identification first, then claims, then risks.
The contents listed by the regulation run in this order: the device name and package contents, the sterility indication and sterilization method, the intended use, single use, storage transport and handling conditions, and warnings and precautions. The first 2 items let the user confirm what has been received; the middle items set the boundaries of use; the last items deliver the risk control measures. This ordering means an IFU cannot be written as a product brochure with an appendix: jumping directly to operating steps while omitting the identification and claims sections leaves the reviewer unable to determine whether the risks were bounded by the preceding conditions at all.
Insight 2: The trigger for each additional element is a device function, and the burden of justifying an omission falls on the applicant.
The additional provisions cover: the statement of Essential Principles already met and possible side effects, identification of combined or connected use, the nature and frequency of installation, calibration, and maintenance, implant-related risks, mutual interference risks, handling of a damaged sterile barrier, cleaning disinfection reconditioning and sterilization procedures with cycle limits for reusable devices, processing required to sterilize the device before use, additional processing before use, the nature type intensity and distribution of radiation where medical radiation is emitted, information on operating changes for devices intended for healthcare professionals and on preparations containing medicinal substances, and the accuracy of measuring devices. None of these applies to every device; the criterion is whether the device has the function. Having the function without writing the section is a missing item; not having the function allows an explicit not applicable statement with a reason.
Insight 3: The IFU, the label, and the technical report must hold three-level consistency of terminology and values.
For the same device, the single-use marking on the label, the prohibition of reprocessing procedures in the IFU, and the materials and design life described in the technical report must point to one conclusion. The high-frequency inconsistency points in practice are accuracy for measuring devices and reprocessing cycles for reusable devices: the label and the technical report each carry one value, the IFU supplies a third, and the file comes back with observations demanding alignment across all three.
Insight 4: The language obligation is a condition of market access, not a matter of delivery format.
A missing Spanish IFU is treated as that item not submitted. In translation, terminology consistency must share the same glossary as the item 6 proposed label; otherwise a single registration ends up carrying two parallel vocabularies for the same parameters.
4. Practical recommendations
- Write against the content list as the skeleton, marking every non-applicable clause as not applicable with its reason.
- For sterile devices, state the sterility indication and the sterilization method, consistent with the validated process of item 9.
- Combine the statement of Essential Principles already met and possible side effects into a dedicated section, not scattered through the operating steps.
- For measuring devices, state the accuracy figures and the conditions of their determination.
- For reusable devices, state the cleaning, disinfection, reconditioning, and sterilization procedures and the cycle limits.
- For devices emitting medical radiation, describe the nature, type, intensity, and distribution of the radiation.
- Maintain a three-level terminology and value comparison table across label, IFU, and technical report, unified before submission.
5. Verification checklist
□ The IFU is in Spanish and shares one terminology glossary with the label
□ Name and package contents, sterility indication and sterilization method, intended use, and single use are included
□ Storage transport and handling conditions, warnings and precautions are included
□ The statement of Essential Principles already met and possible side effects is included
□ Combined or connected use, installation calibration maintenance nature and frequency, implant risks, and mutual interference are stated according to function
□ Reusable devices state the cleaning disinfection reconditioning and sterilization procedures and cycle limits
□ Radiation-emitting and measuring devices state the corresponding content required by the additional provisions
Regulatory information verified as of October 29, 2026.
*GRZAN Regulatory Team*
GRZAN provides medical device registration support in Peru for manufacturers, importers, and authorized representatives, covering Spanish IFU preparation, content clause review, and terminology alignment across the dossier. For inquiries, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us